Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. (Q36524465)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 2006

Language	Label	Description	Also known as
English	Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.	scientific article published on August 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

Europe PubMed Central

Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

systematic review

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Richard M Martin

object named as

Richard M Martin

1

0 references

object named as

David Neal

4

0 references

2

object named as

David Gunnell

1 reference

Europe PubMed Central

14 August 2017

PMC publication ID

5

object named as

Athene Lane

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jenny L Donovan

6

object named as

Jenny Donovan

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

3

object named as

Freddie Hamdy

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

1 August 2006

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Journal of Urology

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

176

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

439-449

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Watchful waiting and factors predictive of secondary treatment of localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Cancer burden in the year 2000. The global picture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Localised prostatic cancer: management and detection issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Relationship between changes in prostate-specific antigen and prognosis of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Natural History of Changes in Prostate Specific Antigen in Early Stage Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

30 September 2017

Progress toward identifying aggressive prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

21 September 2018

Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

21 September 2018

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

21 September 2018

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

21 September 2018

The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

21 September 2018

Tumor cell proliferation and survival in patients with prostate cancer followed expectantly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

21 September 2018

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875171

21 September 2018

Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular prediction of progression in patients with conservatively managed prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Screening for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcome of patients with stage T1a prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: Value of short-term PSADT determinations

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour markers in patients on deferred treatment: prostate specific antigen doubling times

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of repeat sextant biopsies in prostate cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: a seven year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expectant management as an option for men with stage T1c prostate cancer: a preliminary study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a ‘rapid riser’ subset

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16813862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JURO.2006.03.030

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36524465&oldid=1858796655"